[The pharmacokinetics of dihydroergocristine in free-will subjects after oral administration of three formulations].
This paper reports the pharmacokinetics of three dihydroergocristine (DHEC, CAS 17479-19-5) oral formulations in six volunteers. In a randomized crossover trial the volunteers received 6 mg of the drug (1 tablet of 6 mg; 3 ml of drops containing 2 mg/ml; 1 single-dose bottle containing 6 mg); radioimmunoassay was used for the determination of the unchanged drug plasma levels. DHEC shows a plasma profile according to a 3-compartment pharmacokinetic model with a long half-life and high distribution volume. The analysis of AUC0-infinity, Cmax, tmax, and other pharmacokinetic parameters shows that the three formulations investigated are practically bioequivalent.
Coppi
G
G
Forschungszentrum, Poli Industria Chimica S.p.A., Rozzano, Mailand, Italien.
Zanotti
A
A
Mailland
F
F
D000284:Administration, Oral; D000328:Adult; D004088:Dihydroergotoxine / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D008297:Male; D011863:Radioimmunoassay
D004088:Dihydroergotoxine
Untersuchungen zur Pharmakokinetik von Dihydroergocristin bei freiwilligen Probanden nach oraler Verabreichung von drei Formulierungen.